A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

PURPOSE: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated antitumor activity and safety of MEDI0680 plus durvalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, Martin H., Azad, Arun A., Hansen, Aaron R., Gray, Jhanelle E., Welsh, Sarah J., Song, Xuyang, Kuziora, Michael, Meinecke, Lina, Blando, Jorge, Achour, Ikbel, Wang, Yi, Walcott, Farzana L., Oosting, Sjoukje F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365340/
https://www.ncbi.nlm.nih.gov/pubmed/35507017
http://dx.doi.org/10.1158/1078-0432.CCR-21-4115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365340/
https://www.ncbi.nlm.nih.gov/pubmed/35507017
http://dx.doi.org/10.1158/1078-0432.CCR-21-4115

Ejemplares similares